Topic · 3 reports
Anti-Kickback Statute
RegulationWatch reporting on anti-kickback statute matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.
- 340B Program (1)
- Anti-Kickback Statute (3)
- Antitrust (6)
- Controlled Substances Act (3)
- Drug Pricing (8)
- Drug Promotion (1)
- FTC Enforcement (2)
- FTC Report (1)
- False Claims Act (9)
- Marketing Fraud (2)
- Medicare Advantage (1)
- Medicare Negotiation (1)
- Merger Conditions (1)
- Off-Label Promotion (1)
- Opioid Distribution (1)
- Opioid Litigation (4)
- PBM Oversight (1)
- PBM Rebates (7)
- Patent Litigation (1)
- State Enforcement (4)
- Anti-Kickback Statute
Gilead paid its highest prescribers to speak. The settlement was $202 million.
The company admitted paying doctors hundreds of thousands of dollars each. It still describes the programs as education.
- Anti-Kickback Statute
Pfizer paid $2.3 billion over kickbacks, then asked to pay Vyndamax patients' copays. Speaker fees are the route the law still leaves open.
The Anti-Kickback Statute bars paying doctors to prescribe. It still permits paying them to talk about the same drug, and patients never see who was paid.
- Anti-Kickback Statute
Veloxis paid doctors and pharmacies to move a transplant drug, then hid the payments. The bill is over $46 million.
The resolution includes the largest penalty ever for keeping payments out of the public Open Payments database. It was $1.55 million.
